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Although nutritional status may adversely affect various health outcomes, the relationship between
anthropometry and outcomes after hematopoietic cell transplantation (HCT) has not been fully studied in
children. We analyzed the impact of pre-HCT body mass index (BMI), arm muscle area, and arm fat area on
outcomes in 733 patients age 2-18 years who underwent allogeneic HCT for a hematologic malignancy
between 1985 and 2009. We evaluated these 3 variables according to patient group based on age- and sex-
adjusted percentiles for BMI, arm muscle area (<5th, 5th-24th, 25th-94th, and 95th), and arm fat area
(<25th, 25th-94th, and 95th). Cox proportional hazards regression models for event-free survival (EFS),
relapse, and nonrelapse mortality (NRM) at 100 days and 3 years after HCT, as well as grade II-IV acute graft-
versus-host disease (GVHD) and chronic GVHD, were performed using the 3 major variables and adjusted for
covariates. BMI was <5th percentile in only 3% of patients and 95th percentile in 15% of patients, but
outcomes for both groups were similar to those for the BMI 25th-94th percentile group. The BMI 5th-24th
percentile group had lower EFS (P ¼ .01) and higher relapse (P ¼ .003) at day þ100 post-HCT, but these
associations did not hold at 3 years post-HCT. Arm muscle area was <5th percentile in 8% of patients, and arm
fat area was <25th percentile in 10%. Analysis of arm muscle area showed that the <5th percentile group had
lower EFS and higher NRM and relapse rate at day þ100 (P ¼ .002, .04, and .01, respectively) and 3 years (P ¼
.0004, .008, and .01, respectively) post-HCT. Arm fat area <25th percentile was associated with lower EFS at
day þ100 (hazard ratio, 1.5; P ¼ .05), but not at 3 years post-HCT. Anthropometry variables were not asso-
ciated with acute or chronic GVHD. In conclusion, arm muscle area <5th percentile appears to be a stronger
predictor than BMI of poor outcomes after HCT in children with hematologic malignancies.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION The purpose of the present study was to determine
Poor nutritional status is known to adversely affect health
outcomes. The role of nutritional status in children under-
going hematopoietic cell transplantation (HCT) is not fully
understood. Early studies of pediatric HCT using ideal body
weight showed poor survival in underweight patients after
transplantation, but no difference in survival in overweight
patients [1,2]. Since then, body mass index (BMI) has become
a more commonly used index of nutritional status. In 2
studies, overweight patients (BMI 95th percentile) demon-
strated decreased survival compared with non-overweight
children [3,4].
BMI might not be the best indicator of nutritional status
or body composition in pediatric HCT patients given that BMI
only indicates weight relative to height (body size), and
cannot discriminate between fat and muscle mass [5]. But
body composition can be estimated by arm anthropometry,
which measures peripheral tissue and provides an approxi-
mation of whole-body muscle and fat mass. Although arm
anthropometry is not widely done, it is routinely performed
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13.04.017whether BMI and body composition as measured by arm
anthropometry are associated with survival outcomes and
the development of acute and chronic graft-versus-host
disease (GVHD) in a large population of pediatric patients
undergoing HCT for hematologic malignancies.
PATIENTS AND METHODS
Patient Selection
Between 1985 and July 1, 2009, 822 consecutive children age 2-18 years
underwent myeloablative conditioning and allogeneic HCT for a hemato-
logic malignancy at the Fred Hutchinson Cancer Research Center (FHCRC) in
Seattle. Thirty-two of these patients were excluded from the present anal-
ysis, including 9 who received a T celledepleted allograft, 6 who did not
consent to follow-up, 5 who received 131iodine therapy, 5 with Down
syndrome, 4 who received 10-Gy single-fraction total body irradiation (TBI),
and 3 identical twin donor allograft recipients. The remaining 790 patients
or their responsible guardians consented to follow-up under Protocol 999.2,
and the data were reviewed under Protocol 1782 approved by the FHCRC
Institutional Review Board.
Anthropometric data were unavailable for 57 patients (23 for undocu-
mented reasons, 20 for patient refusal or uncooperativeness, 9 not tested
owing to direct hospital admissions, 4 for obesity, and 1 with missing data),
leaving a total of 733 patients for analysis. Compared with the patients with
anthropometric data, the 57 patients without anthropometric data were
younger (7.5 years versus 10.4 years; P< .001) at time of transplantation, but
there were no statistical differences in transplantation outcomes (data not
shown).
Preparative Regimens, Stem Cell Sources, and Supportive Care
Transplantation preparative regimens included either chemotherapy or
chemoradiotherapy as described previously [6-10]. Most chemotherapy-onlyTransplantation.
Table 1
Patient and Transplantation Characteristics
Characteristic Value
Number of patients 733
Age at HCT, yr, median (range) 9.2 (2.0-17.9)
Sex, n (%)
Female 297 (40)
Male 436 (60)
Race/ethnicity, n (%)
Non-Hispanic white 574 (78)
Other race/ethnicity 159 (22)
Diagnosis at HCT, n (%)
ALL 395 (54)
AML 189 (26)
CML 89 (12)
Juvenile myelomonocytic leukemia 15 (2)
Myelodysplastic syndrome 45 (6)
Disease phase, n (%)
Good 410 (56)
Poor 323 (44)
Donor type for ﬁrst HCT, n (%)
Related (parent or relative) 159 (22)
Unrelated 269 (37)
Sibling 305 (41)
HLA matching, n (%)
Matched 475 (65)
Mismatched 258 (35)
Stem cell source at ﬁrst HCT, n (%)
Bone marrow 645 (88)
Peripheral blood 50 (7)
Cord blood 38 (5)
HCT preparative regimen, n (%)
Fractionated 12-15.75 Gy TBI 637 (87)
NoneTBI-containing regimens
Busulfan þ cyclophosphamide 86 (12)
Other 10 (1)
Acute GVHD prophylaxis agents, n (%)
1 103 (14)
2 562 (77)
3þ 68 (9)
Acute GVHD grade, n (%)*
0-I 190 (26)
II-IV 541 (74)
Clinical extensive chronic GVHD
(yes/evaluable), n (%)
241/526 (46)
* Two patients were not evaluable for acute GVHD.
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busulfan 4 mg/kg/day for 4 days [6,8]. Most of the busulfan and cyclophos-
phamide doses were calculated using adjusted body weight if the patient’s
actual weight was >100% of ideal body weight, when dosing was based on
per-kilogram weight. Since 1992, most busulfan doses have been adjusted
based on pharmacokinetic levels [11]. Most TBI regimens included cyclo-
phosphamide 60 mg/kg/day for 2 days. Between 1985 and 2000, TBI was
delivered from dual opposing cobalt-60 sources at a dose rate in air of
5-8 cGy/min as fractionated TBI, with exposures of 2.0-2.75 Gy for 6-7
consecutive days orhyperfractionated exposures of 1.2Gy2-3 timesdaily for 4
consecutive days [6,9,10]. Starting in 2001, TBI has been delivered by a linear
accelerator.
The allogeneic transplantation recipients received bone marrow, pe-
ripheral blood, or umbilical cord blood stem cells harvested from related or
unrelated donors. All allogeneic transplantation recipients received prophy-
laxis for acuteGVHDdependingon the type of donorandprotocol in use at the
time of HCTand generally including eithermethotrexate ormethotrexate and
a calcineurin inhibitor, but less often including corticosteroids, antithymocyte
globulin, mycophenolate mofetil, or monoclonal antibodies as additional
prophylactic agents [12-14]. Acute and chronic GVHDwere diagnosed, graded,
and treated as described previously [15-18].
All surviving patients underwent evaluation for engraftment and
chronic GVHD at 80-100 days after transplantation. Patients returned to the
FHCRC for long-term follow-up at 1 year and electively thereafter. Follow-up
after 1 year consisted of annual contact with referring physicians between
1985 and 1990, and questionnaires mailed annually to patients and their
primary medical providers from 1991 to present.
Study Data
Data were obtained from the FHCRC clinical information database,
transplantation ﬂowsheets, nutritional records, and long-term follow-up
records. Study data were collected through July 1, 2012.
BMI (in kg/m2) was calculated based on patient height and weight at the
time of HCT. Sex- and age-adjusted BMI was calculated using the 2000
Centers for Disease Control and Prevention’s BMI for age growth charts to
obtain percentile rankings [19]. Patients were divided into 4 BMI categories:
underweight (<5th percentile), at risk for underweight (5th to <25th
percentile), normal and at risk for overweight (25th to <95th percentile),
and overweight (95th percentile).
Arm anthropometry was performed by registered dietitians. Mid-upper
arm circumference was measured with ﬂexible tape to the nearest 0.1 cm,
and triceps skin fold thickness was measured with a Harpenden skinfold
caliper as the average of 3 measurements taken to the nearest 0.2 mm at the
halfway point between the acromion and olecranon process of the right
upper arm. Arm muscle area and arm fat area z-scores were calculated
according to the equations and age and sex-matched norms of Frisancho
[20] and expressed as percentiles. Patients were divided into 4 arm muscle
area categories: <5th percentile, 5th to <25th percentile, 25th to <95th
percentile, and 95th percentile. Because of a limited number of patients in
the <5% percentile category, arm fat area was collapsed into 3 categories:
<25th percentile, 25th to <95th percentile, and 95th percentile.
Study Endpoints, Variables, and Statistical Methods
For the purpose of analysis, patient diagnoses at HCT were categorized
into 4 groups: acute lymphoblastic leukemia (ALL), acute myelogenous
leukemia (AML), chronic myelogenous leukemia (CML), and juvenile mye-
lomonocytic leukemia andmyelodysplastic syndrome. Variables selected for
adjustment included sex, race/ethnicity (non-Hispanic white versus other
race/ethnicity), diagnosis, time from diagnosis to HCT (<1 year versus
1 year), age at HCT (2-9 years versus 10-18 years), TBI (yes/no), donor type
(related versus unrelated), donorerecipient HLA-matching (matched or
mismatched, deﬁned as at least 1 antigen mismatch at HLA-A, -B, or -DRB1),
acute GVHD prophylaxis (use of 1, 2, or 3 or more prophylactic drugs), and
disease status. For the latter, good risk included ALL and AML in ﬁrst or
second complete remission (CR), CML in chronic phase, juvenile myelomo-
nocytic leukemia and myelodysplastic syndrome, and myelodysplastic
syndrome in refractory anemia or refractory anemia with ringed side-
roblasts, and poor risk included ALL and AML in active relapse or third or
greater CR, CML in acute phase or blast crisis, andmyelodysplastic syndrome
in refractory anemia with excess blasts or excess blasts in transformation.
Primary endpoints were nonrelapse mortality (NRM), relapse, and
event-free survival (EFS) over the ﬁrst 100 days and the ﬁrst 3 years
posttransplantation, and the development of grade II-IV acute GVHD and
clinical extensive chronic GVHD. NRM was deﬁned as death in CR. Relapse
was deﬁned as recurrence of disease in bone marrow. EFS was deﬁned as
survival without death, relapse, graft failure, or secondary malignancy.
All endpoints were adjusted for diagnosis, sex, race/ethnicity, age at HCT,
TBI, donor type, and HLA matching. NRM, EFS, and relapse were alsoadjusted for disease status and time from diagnosis to HCT. Acute GVHDwas
also adjusted for acute GVHD prophylaxis.
Survival curves were estimated by the Kaplan-Meier method. Cox
regression was used for hazard ratio (HR) analysis, with adjustment for
covariates. NRM and relapse were treated as mutually competing risks.
Death was treated as a competing risk for analysis of acute and chronic
GVHD. Overall tests of signiﬁcance reﬂect likelihood ratio tests; comparisons
of individual levels to the reference level reﬂect Wald tests. All P values are
2-sided. Descriptive data were analyzed using SPSS software (IBM, Armonk,
NY). Descriptive statistics are reported as mean and range.
RESULTS
Patient Population
Patient and transplantation characteristics are presented
in Table 1. The study population comprised 733 patients, of
whom 60% were male, 54% had ALL and 26% had AML, 56%
were good risk, and 65% had received a HLA-matched
transplantation from a sibling (41%), unrelated (37%), or
other related (22%) donor. The distribution of patient BMI
and arm anthropometry is shown in Table 2. Three percent of
the patients were underweight (BMI <5th percentile), and
15% were overweight (BMI 95th percentile). Arm muscle
area was very low (<5th percentile) in 8%, and arm fat area
was low (<25th percentile) in 10%. Pearson correlation
coefﬁcients for the 3 measures were as follows: BMI with
arm muscle area, r ¼ 0.60, P < .0001; BMI with arm fat area,
Table 2
Distribution of Arm Anthropometry Measurements by BMI
BMI N Arm Muscle Area, n (%) Arm Fat Area, n (%)
<5th 5th-24th 25th-94th 95th <25th 25th-94th 95th
<5th 21 11 (52) 10 (48) d d 14 (67) 7 (33) d
5th-24th 67 24 (36) 28 (42) 15 (22) d 21 (31) 46 (69) d
25th-94th 533 22 (4) 173 (32) 324 (61) 13 (2) 40 (8) 395 (74) 97 (18)
95th 113 1 (1) 9 (8) 78 (69) 25 (22) d 38 (34) 75 (66)
Total 733 58 (8) 220 (30) 417 (57) 38 (5) 75 (10) 486 (66) 172 (23)
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r ¼ 0.32, P < .0001 (data not shown).
EFS
Transplantation outcomes by BMI and arm anthropom-
etry are presented in Table 3. When categorized according to
BMI, EFS at day þ100 was 60% for the 5th-24th percentile
group and 72% for the 25th-94th percentile group (Figure 1).
As shown in Table 4, in multivariate analysis, the BMI 5th-
24th percentile group was associated with a lower EFS at
dayþ100 (HR,1.7; P¼ .01), but this associationwas no longer
signiﬁcant (HR, 1.3; P ¼ .09) at 3 years after HCT.
When categorized according to arm muscle area, EFS at
day þ100 was 52% for the <5th percentile group and 69% for
the 25th-94th percentile group. At 3 years post-HCT, EFS had
dropped to 22% for the arm muscle area <5th percentile
group and 42% for the 25th-94th percentile group (Figure 2).
In multivariate analysis, arm muscle area <5th percentile
was signiﬁcantly associated with decreased EFS at day þ100
(HR, 2.0; P ¼ .002) and 3 years (HR, 1.8; P ¼ .0004) post-HCT.
When categorized according to arm fat area, EFS at
day þ100 post-HCT was 59% for the <25th percentile group
and 70% for the 25th-94th percentile group. At 3 years post-
HCT, EFS had dropped to 32% for the arm fat area <25th
percentile group and to 42% for the 25th-94th percentile
group. In multivariate analysis, arm fat area<25th percentile
was associated with EFS at day þ100 (HR, 1.5; P ¼ .05), but
not at 3 years (HR, 1.3; P ¼ .09), post-HCT.
NRM
In multivariate analysis, BMI and arm fat area were not
associated with NRM at day þ100 or 3 years post-HCT.
Among the arm muscle area groups, the <5th percentile
group had a 26% NRM at day þ100, compared with 16% forTable 3
BMI, Arm Anthropometry, and Transplantation Outcomes
N EFS,
Day þ100
NRM,
Day þ100
Relapse,
Day þ100
Acute G
BMI, n (%)
<5th 21 13 (67) 3 (14) 4 (19) 10 (48
5th-24th 67 40 (60) 12 (18) 14 (21) 46 (69
25th-94th 533 382 (72) 86 (16) 57 (11) 398 (75
95th 113 74 (65) 22 (19) 17 (15) 87 (77
P value .10 .05 .71 .04
Arm muscle area, n (%)
<5th 58 30 (52) 15 (26) 12 (21) 41 (71
5th-24th 220 159 (72) 36 (16) 24 (11) 162 (74
25th-94th 417 289 (69) 67 (16) 54 (13) 314 (75
95th 38 31 (82) 5 (13) 2 (5) 24 (63
P value .009 .06 .21 .71
Arm fat area, n (%)
<25th 75 44 (59) 13 (17) 15 (20) 48 (64
25th-94th 486 341 (70) 78 (16) 62 (13) 356 (73
95th 172 124 (72) 32 (19) 15 (9) 137 (80
P value .13 .16 .79 .16
* Chronic GVHD (clinical extensive divided by number evaluable).the 25th-94th percentile group. At 3 years post-HCT, NRM
had increased to 38% for the <5th percentile group and 24%
for the 25th-94th percentile group. In multivariate analysis,
the HR of NRM at day þ100 was nearly 2-fold higher for the
arm muscle area <5th percentile group compared with the
25th-94th percentile group (HR, 1.88; P ¼ .04), and this
association was even more signiﬁcant at 3 years (HR, 1.94;
P ¼ .008).
Relapse
Among the BMI groups, relapse at day þ100 post-HCT
was 21% for the 5th-24th percentile group and 11% for the
25th-94th percentile group. In multivariate analysis, the BMI
5th-24th percentile group was associated with a 2- to 3-fold
increased risk of relapse at day þ100 (HR, 2.5; P ¼ .003), but
the association was no longer signiﬁcant at 3 years post-HCT
(HR, 1.3; P ¼ .23). In the arm muscle area <5th percentile
group, 21% of patients had relapsed at day þ100, repre-
senting a 2- to 3-fold increased risk compared with the 25th-
94th percentile group (HR, 2.4; P ¼ .01), and this association
remained signiﬁcant at 3 years post-HCT (HR, 1.8; P ¼ .01).
Arm fat area was not associated with relapse at day þ100 or
3 years post-HCT.
Acute and Chronic GVHD
As shown in Table 3, BMI was associated (P ¼ .04) with an
increased incidence of acute GVHD, which rose from 48% in
the <5th percentile group to 77% in the 95th percentile
group, but arm muscle area and arm fat area were not
associated with acute GVHD. We found no signiﬁcant asso-
ciations between chronic GVHD and BMI, armmuscle area, or
arm fat area. None of the anthropometric measures tested
here were associated with acute or chronic GVHD in multi-
variate analysis (data not shown).VHD Chronic GVHD* EFS, 3 Year NRM, 3 Year Relapse,
3 Year
) 2/13 (15) 6 (29) 5 (24) 10 (48)
) 20/40 (50) 26 (39) 18 (27) 23 (34)
) 182/395 (46) 231 (43) 126 (23) 171 (32)
) 37/78 (47) 42 (37) 31 (27) 40 (35)
.16 .12 .16 .50
) 11/29 (38) 13 (22) 22 (38) 23 (40)
) 76/166 (46) 93 (42) 52 (24) 74 (34)
) 137/300 (46) 175 (42) 99 (24) 137 (33)
) 17/31 (55) 20 (53) 6 (16) 11 (29)
.78 .002 .08 .02
) 16/48 (33) 24 (32) 20 (27) 31 (41)
) 160/351 (46) 204 (42) 115 (24) 159 (33)
) 65/127 (51) 73 (42) 44 (26) 55 (32)
.06 .13 .14 .68
Figure 1. EFS by BMI percentile category: <5th, 5th-24th, 25th-94th, and
95th. The P values for unadjusted comparisons among the 4 categories
were as follows: <5th versus 25th-94th, P ¼ .13; 5th-24th versus 25th-94th,
P ¼ .12; 95th versus 25th-94th, P ¼ .09). Adjusted P values are presented in
Table 4.
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Mortality was 78% among the 58 patients in the arm
muscle area <5th percentile group, higher (94%) in the 33
poor-risk patients and lower (56%) in the 25 good-risk
patients. Before day þ100 post-HCT, 6 patients died from
regimen-related toxicity, 4 from relapse, 4 from grade IV
acute GVHD, 4 from infections (2 cytomegalovirus, 2 fungal),
and 3 from respiratory failure. After day þ100, 17 patients
died from relapse, 4 from infections (2 fungal, 1 cytomega-
lovirus, 1 staphylococcus), 1 from gastrointestinal hemor-
rhage, 1 from graft failure, and 1 from an unknown cause.
The distribution of BMI weight categories in the arm
muscle area <5th percentile group was 19% (11 of 58)Table 4
Multivariate Analysis
EFS to Day þ100 NRM t
HR (95% CI) P HR (95
BMI
<5th 1.62 (0.8-3.4) .20 1.09 (0
5th-24th 1.73 (1.1-2.6) .01 1.36 (0
25th-94th 1.0 e 1.0
95th 1.18 (0.8-1.7) .38 1.31 (0
Arm muscle area
<5th 2.03 (1.3-3.2) .002 1.88 (1
5th-24th 0.99 (0.7-1.4) .94 1.12 (0
25th-94th 1.0 e 1.0
95th 0.59 (0.3-1.3) .18 0.86 (0
Arm fat area
<25th 1.53 (1.0-2.3) .05 1.36 (0
25th-94th 1.0 e 1.0
95th 0.93 (0.7-1.3) .66 1.07 (0
EFS to 3 Yrs NRM
HR (95% CI) P HR (9
BMI
<5th 1.42 (0.8-2.4) .20 1.32 (
5th-24th 1.33 (1.0-1.9) .09 1.42 (
25th-94th 1.0 e 1.0
95th 1.17 (0.9-1.5) .26 1.37 (
Arm muscle area
<5th 1.83 (1.3-2.6) .0004 1.94 (
5th-24th 1.01 (0.8-1.3) .92 1.04 (
25th-94th 1.0 e 1.0
95th 0.74 (0.5-1.2) .22 0.58 (
Arm fat area
<25th 1.32 (1.0-1.8) .09 1.53 (
25th-94th 1.0 e 1.0
95th 0.98 (0.8-1.2) .88 1.04 (underweight, 41% at risk for underweight, 38% normal and at
risk for overweight, and 2% overweight. At presentation for
HCT, all of these patients had a normal serum creatinine
level, and 14 patients had hypoalbuminemia (serum albumin
<3.3 g/dL), 7 of whom had received total parental nutrition
and/or nasogastric tube feeding. Seven other patients had
received nutritional support for a history of gastrointestinal
infections (n¼ 4) or weight loss, poor feeding, and stomatitis
(n ¼ 3).DISCUSSION
This is the ﬁrst study to report an association between
arm anthropometry and transplantation outcomes in a large
population of pediatric HCT recipients. Amajor ﬁnding of this
study is that arm anthropometry is a better predictor of poor
outcomes than the more commonly used BMI. Speciﬁcally,
patients with pretransplantation arm muscle area <5th
percentile had inferior EFS at dayþ100 and 3-years post-HCT
owing to increased rates of relapse and NRM. Sarcopenia
(low muscle mass) has been associated with toxicity in adult
cancer patients receiving chemotherapy, and malnourished
cancer patients are at increased risk for infection [21-23].
Our NRM data are consistent with these observations, in
that among the group with armmuscle area<5th percentile,
14% died from infection, 10% died from regimen-related
toxicity, and 5% died from respiratory failure; however,
whether malnutrition increases the risk of relapse has not
been clearly demonstrated. We could only identify 1 study
showing an association of severely reduced protein energy
reserves with an increased risk of relapse [24]. In our study,
the 3 year posttransplantation relapse rate was almost 2-fold
higher (HR, 1.81) in the arm muscle area <5th percentileo Day þ100 Relapse to Day þ100
% CI) P HR (95% CI) P
.3-3.6) .88 1.88 (0.6-5.6) .25
.7-2.5) .33 2.54 (1.4-4.7) .003
e 1.0 e
.8-2.1) .28 1.32 (0.8-2.3) .32
.0-3.4) .04 2.39 (1.2-4.8) .01
.7-1.7) .59 0.97 (0.6-1.6) .91
e 1.0 e
.3-2.2) .75 0.43 (0.1-1.8) .24
.7-2.6) .34 1.46 (0.8-2.6) .22
e 1.0 e
.7-1.6) .74 0.79 (0.4-1.4) .42
to 3 Yrs Relapse to 3 Yrs
5% CI) P HR (95% CI) P
0.5-3.3) .55 1.50 (0.8-2.9) .23
0.9-2.3) .18 1.32 (0.8-2.1) .23
e 1.0 e
0.9-2.1) .13 1.19 (0.8-1.7) .34
1.2-3.2) .008 1.81 (1.1-2.9) .01
0.7-1.5) .85 1.09 (0.8-1.5) .56
e 1.0 e
0.3-1.3) .20 0.87 (0.5-1.6) .65
0.9-2.5) .10 1.31 (0.9-2.0) .19
e 1.0 e
0.7-1.5) .82 1.06 (0.8-1.4) .73
Figure 2. EFS by arm muscle area percentile category: <5th, 5th-24th, 25th-
94th, and 95th. The P values for unadjusted comparisons among the 4
categories were as follows: <5th versus 25th-94th, P ¼ .0002; 5th-24th versus
25th-94th, P ¼ .77; 95th versus 25th-94th, P ¼ .22). Adjusted P values are
shown in Table 4.
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underlying malignancies, despite our attempt to adjust for
disease status in the multivariate analysis. Further investi-
gation into the potential relationship between reduced
muscle mass and risk of relapse may be warranted.
Underweight and overweight patients are generally
considered at risk for poor outcomes. In our study, over-
weight patients had a lower EFS at day þ100 post-HCT
compared with non-overweight patients (65% versus 70%),
but the differencewas not signiﬁcant inmultivariate analysis.
In contrast, underweight (BMI 5th-24th percentile) patients
had signiﬁcantly reduced EFS at day þ100 (HR, 1.7; P ¼ .01).
Similarly, the very underweight (BMI <5th percentile)
patients had a lower EFS at day þ100 (HR, 1.6; P ¼ .20), but
this was not statistically signiﬁcant, possibly owing to the
small number of patients. Thus, patients with BMI <25th
percentile appear to be at greater risk for decreased EFS at
day þ100 post-HCT compared with normal-to-overweight
patients, but this risk did not extend to 3 years post-HCT.
Our ﬁndings regarding BMI and survival differ from those
of 2 previous studies of pediatric HCT recipients [3,4], despite
similar proportions of underweight and overweight patients.
In our study, 3% of patients were underweight (BMI <5th
percentile) and 15%were overweight (BMI95th percentile),
comparable to the 9%with BMI<5th percentile,11%with BMI
<10th percentile, and 11%-17% overweight in the previous
studies [3,4]. Those 2 studies showed poorer survival in
overweight children compared with non-overweight chil-
dren. In a multicenter study of 1281 children with aplastic
anemia, overall survival was lower in overweight children
compared with non-overweight children (65% versus 69%)
[4]. In a single-institution study of 325 children with various
diseases (27% nonmalignant), overall survival and EFS at 5
years post-HCT were lower in overweight compared with
non-overweight children (47% versus 60% [P ¼ .02] and 42%
versus 58% [P ¼ .02], respectively) [3]. In our study, EFS at 3
years post-HCT was lower in overweight children compared
with non-overweight children (37% versus 42%), but the
difference was not statistically signiﬁcant. One possible
explanation for the lower survival seen in our study
compared with previous studies is that the children in our
cohort all had underlying malignancies, whereas the other
study cohorts were entirely or partially composed of patients
with nonmalignant diseases not at risk for relapse.
Taken together, the data suggest that the prognostic
relevance of BMI on posttransplantation survival might bedisease-speciﬁc. High BMI appears to be associated with
lower survival in patients with nonmalignant disease, but for
patients with malignant disease, our ﬁndings do not support
any association of BMI with survival other than short-term
EFS in the underweight BMI category.
Although BMI is the most commonly used index of body
composition, it may lack discriminatory power as a predictor
of posttransplantation outcome, given that it indicates
weight relative to height (ie, body size) but cannot distin-
guish between fat and muscle mass. A previous study found
that BMI was a poor predictor of nutritional status in the 30%
of female children and 69% of male children with suboptimal
nutritional status before HCT, as determined by body cell
mass [5]. Eight percent of children in our cohort had low
peripheral muscle mass, with arm muscle area <5th
percentile, similar to a previous study reporting 7% of
patients with muscle wasting before HCT [25]. The etiology
of reduced muscle mass does not appear to be entirely
related to energy intake, considering that 40% of the children
with low arm muscle area in our cohort had a BMI >25th
percentile. Muscle loss also might be related to infectious
complications, the primary disease, or therapy. Weight loss
often precedes a diagnosis of hematologic malignancy and
frequently occurs during chemotherapy; for example, a study
of childhood ALL showed a 5% reduction in the ratio of lean
mass to total body weight after 6 months of therapy [26]. In
our study, infection did not appear to be a major cause of
muscle loss, given that only 7% of the low arm muscle area
group had a gastrointestinal infection before HCT.
Our ﬁndings conﬁrm that BMI does not increase the risk
of acute GVHD. Barker et al. [4] found that BMI at the time of
HCT did not increase the adjusted risk of grade III-IV acute
GVHD. In this study, we did not ﬁnd any association between
grade II-IV acute GVHD and BMI or between anthropometry
and chronic GVHD.
Arm anthropometry provides a simple, easily performed,
and low-cost measurement of body composition. But
although arm anthropometry provides an approximation of
total body muscle mass, it does not provide a direct measure,
as can be obtained by dual-energy X-ray absorptiometry
(DEXA). Whether arm anthropometry is equivalent to DEXA
as a measure of body composition has not been clearly
established. Mid-upper arm circumference is highly corre-
lated with lean body mass, but skinfold measurements may
underestimate whole body fat as measured by DEXA [27,28].
Further investigation into the validity of arm anthropometry
and DEXA scanning may be warranted.
In addition to measurements of body composition, iden-
tiﬁcation of sarcopenia by biological markers may be of
interest. During chemotherapy for childhood ALL, serum
albumin was abnormally low in the majority of patients, and
in another study, lean body mass from DEXA scans was
correlated with increased serum creatinine concentration
(r ¼ 0.52; P < .001) [26,29]. In the present study, all patients
in the arm muscle area <5th percentile group had a normal
serum creatinine concentration, but 24% had a low serum
albumin level at the time of HCT.
This study had several limitations, including its retro-
spective nature and a population with heterogeneous
diagnoses and treatments. In addition, because nutritional
status in children before HCT can be a surrogate for disease
status or complications of previous therapy, it is possible
that despite statistical adjustments for disease status, our
ﬁndings may be related to other variables that were not
considered. Population values were unavailable for BMI in
P.A. Hoffmeister et al. / Biol Blood Marrow Transplant 19 (2013) 1081e10861086patients age <2 years because arm anthropometry in infants
is unreliable, which limits the generalizability of our ﬁnd-
ings to this population. As discussed earlier, measurement
of total body composition by DEXA might have yielded
different results than those obtained by arm anthropometry.
We were unable to evaluate the potential impact of differ-
ences in preparative regimen-speciﬁc chemotherapy doses
or dose adjustments for overweight patients or based on
pharmacokinetic levels, because these data are not routinely
collected. Finally, underweight patients who have lost
weight compared with baseline may fare differently than
patients with a low baseline weight; however, adjusting for
pretransplantation weight change was beyond the scope of
this study.
CONCLUSION
Our data suggest that although low BMI is associated with
lower day þ100 EFS, low pretransplantation muscle mass as
measured by arm anthropometry is a better predictor of
reduced EFS, increased NRM, and increased relapse at both
day þ100 and 3 years post-HCT in children undergoing
transplantation for hematologic malignancy. Given the
potential impact of body composition on a child undergoing
HCT, patients should undergo nutritional status assessment
before HCT. Although not the focus of the present study, our
ﬁndings suggest that patients with low BMI, and especially
patients with pretransplantation muscle wasting, might
beneﬁt from increased preemptive nutritional monitoring
and support. Further research on the optimal assessment of
body composition and its role as a potential risk factor in
transplantation recipients is needed.
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